• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    SC 13G/A 1 d890082dsc13ga.htm NATERA, INC. Natera, Inc.

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Natera, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    632307104

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 632307104    

     

     1.   

    Names of Reporting Persons

     

    Alger Associates, Inc. 13-3017981

     2.   

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐  (b) ☐

     

     3.   

    SEC Use Only

     

     

     4.   

    Citizenship or Place of Organization

     

    New York

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

        5.    

    Sole Voting Power

     

    3,585,861

        6.    

    Shared Voting Power

     

    0

        7.    

    Sole Dispositive Power

     

    4,011,957

        8.    

    Shared Dispositive Power

     

    0

     9.   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,011,957

    10.   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.   

    Percent of Class Represented by Amount in Row (9)

     

    3.2%

    12.   

    Type of Reporting Person (See Instructions)

     

    HC

     

    2


    Item 1.
          (a)    Name of Issuer
        

    Natera, Inc.

      (b)    

    Address of Issuer’s Principal Executive Offices

    13011 McCallen Pass

    Building A, Suite 100

    Austin, TX 78753

    Item 2.
      (a)    Name of Person Filing
        

    Alger Associates, Inc.

      (b)    Address of Principal Business Office or, if none, Residence
        

    100 Pearl Street, 27th Floor, New York, NY 10004

      (c)    Citizenship
        

    New York

      (d)    Title of Class of Securities
        

    Common Stock

      (e)    CUSIP Number
        

    632307104

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a)   

    ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

      (b)   

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

      (c)   

    ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

      (d)   

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

      (e)   

    ☐   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

      (f)   

    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

      (g)   

    ☒   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

      (h)   

    ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

      (i)   

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

      (j)   

    ☐   A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

      (k)   

    ☐   Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:          

     

    3


    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

       (a)    Amount beneficially owned:
         

    4,011,957

       (b)     Percent of class:
         

    3.2%

             (c)    Number of shares as to which the person has:
         

     

           (i)    Sole power to vote or to direct the vote
            

    3,585,861

           (ii)    Shared power to vote or to direct the vote
            

    0

           (iii)    Sole power to dispose or to direct the disposition of
            

    4,011,957

           (iv)    Shared power to dispose or to direct the disposition of
            

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC (“FAM”), a registered investment adviser, and Weatherbie Capital, LLC (“WC”), a registered investment adviser. Each of FAM and WC is a 100% owned subsidiary of Alger Group Holdings, LLC (“AGH”), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    See Exhibit A

     

    Item 8.

    Identification and Classification of Members of the Group

     

    Item 9.

    Notice of Dissolution of Group

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    4


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    By:   Alger Associates, Inc.
    By:  

    /s/ Hal Liebes

    Name:   Hal Liebes
    Title:   Secretary
    Date:   November 14, 2024

     

    5


    Exhibit A

    Subsidiary

    Alger Group Holdings, LLC — HC

    Fred Alger Management, LLC — IA

    Weatherbie Capital, LLC — IA

    Get the next $NTRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    12/29/2023$75.00 → $85.00Buy
    BTIG Research
    12/14/2023$70.00Buy
    Guggenheim
    12/13/2023$70.00Outperform
    Wolfe Research
    More analyst ratings

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Natera Inc.

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      11/14/24 4:02:50 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Natera Inc. (Amendment)

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      6/7/24 12:07:25 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Natera Inc. (Amendment)

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      2/14/24 4:06:56 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Natera Announces Medicare Coverage for Signatera™ Genome

      Broad coverage, inclusive of all previously covered Signatera indications Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monitoring, mirroring the pre-existing coverage for Signatera. The coverage determination was supported by robust evidence on the validity of the genome-based assay, leveraging the extensive body of literature validating Signatera in over 100 published clinical

      6/4/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

      Overall pan-cancer sensitivity of 94% and specificity of 100%, with analytical detection down to 1 PPM Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study analyzed the performance of Signatera Genome in a cohort of 392 patients (> 2,600 plasma samples) across five different tumor types (breast cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and colorectal cancer). Key results included: Excellent pan-cancer performance: Signatera G

      6/2/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

      Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay GI, GU, Skin, Sarcoma: Significance of Signatera MRD and dynamics to predict recurrence, progression, and treatment response across multiple disease subtypes  Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today annou

      5/22/25 5:08:00 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Financials

    Live finance-specific insights

    See more
    • Natera Reports First Quarter 2025 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

      5/8/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera to Report its First Quarter Results on May 8, 2025

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2025 Financial Results Date: May 8, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-596-4144 (Domestic) 1-646-968-2525 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/454317205 A webcast replay will be available at

      5/1/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Reports Fourth Quarter and Full Year 2024 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues grew 53.9% over the same period. Generated a gross margin of 62.9% in the fourth quarter of 2024, compared to a gross margin of 51.4% in the fourth quarter of 2023. Generated total revenues of $1,696.9 million in the full year of 2024, compared to $1,082.6 million in the full year 2023, an increase of 56.7%

      2/27/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on Natera with a new price target

      RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00

      3/13/25 8:17:14 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Natera with a new price target

      Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00

      1/23/25 7:51:22 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Jefferies resumed coverage on Natera with a new price target

      Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00

      6/3/24 8:16:05 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.

      SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)

      5/14/25 10:45:26 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Natera Inc.

      10-Q - Natera, Inc. (0001604821) (Filer)

      5/8/25 7:35:38 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Natera, Inc. (0001604821) (Filer)

      5/8/25 4:15:22 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marcus Gail Boxer sold $657,761 worth of shares (4,000 units at $164.44), decreasing direct ownership by 41% to 5,704 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      6/11/25 9:05:04 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $471,212 worth of shares (3,000 units at $157.07), decreasing direct ownership by 2% to 133,205 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      6/4/25 9:05:06 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Chapman Steven Leonard sold $960,062 worth of shares (6,111 units at $157.10), decreasing direct ownership by 3% to 179,071 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      6/4/25 9:05:04 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

      Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

      6/5/23 11:06:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

      Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

      2/23/23 8:05:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

      AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

      5/24/22 8:03:00 AM ET
      $NTRA
      Medical Specialities
      Health Care